Imatinib has revolutionized the treatmentof Chronic Myeloid Leukemia (CML) by targeting the abnormal protein responsiblefor the uncontrolled growth of cancer cells. It has significantly improvedsurvival rates and quality of life for CML patients. The role of the
Imatinib manufacturer is critical in making this life-saving drug accessible topatients globally. By ensuring high production standards and competitivepricing, manufacturers help reduce the cost of treatment and enhanceavailability, allowing more patients to benefit from this breakthrough therapyin the fight against CML.<o:p></o:p>
